Skip to main content

Vaccine Responses in Patients with B Cell Malignancies

CLL/SLL Malignancy Clinical Trial Investigating Vaccine Effectiveness

a patient receiving a vaccine

Researchers at the National Institutes of Health (NIH) are seeking volunteers with CLL/SLL to participate in a vaccines study with FDA-approved and/or FDA-authorized vaccines. Volunteers will participate in the study for 6 months.

You may be eligible for the study, if you:

  • Are at least 18 years old
  • Have a diagnosis of Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), AND
  • Are currently receiving treatment for your CLL/SLL (e.g. ibrutinib, acalabrutinib or venetoclax)
  • Have not received IVIG (intravenous immunoglobulin) in the past 3 months
  • Have not received anti-CD20 and/or anti-CD19 antibody therapy in the past 6 months
  • Have not previously received an allogeneic stem cell transplant

The NIH Clinical Center, America's Research Hospital located in Bethesda, MD.
Metro red line (Medical Center stop).

For more information:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
TTY users dial 7-1-1
Email: ccopr@nih.gov

Or go online:
bit.ly/3SyrL1A
Refer to study #000444-H

Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Heart, Lung and Blood Institute (NHLBI)